Sharekhan Triumphs Again with Top Industry Recognitions in 2024 aninews.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from aninews.in Daily Mail and Mail on Sunday newspapers.
Traction for its specialty portfolio, a strong showing in the domestic market, and better regulatory compliance are positives for the country s largest pharmaceutical (pharma) company, Sun Pharmaceutical Industries.
Given the triggers, some brokerages have increased their earnings per share estimates and target price for 2024-25 (FY25).
This should sustain the momentum for the stock, which has been one of the major pharma gainers in 2023-24 (FY24), rising 57 per cent. It is currently trading at Rs 1,547 per share.
10 non-bank and non-finance stocks from the BSE500 Index universe that offer an optimal blend of low valuation, reasonably robust revenue and earnings growth in recent quarters, a strong balance sheet, and most importantly, positive cash flow from their operations.